文献速递姑息放疗与转移瘤

舒尼替尼联合同步放疗治疗不可手术肉瘤:多中心Ⅰ期研究剂量递增与扩展部分的最终结果

Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study.
PubMed 文献 · Radiother Oncol · 2022-01-21

这项法国多中心3+3剂量递增Ⅰ期研究评估舒尼替尼持续给药联合同步放疗治疗不可手术非GIST肉瘤的可行性与安全性;DL1(25 mg/天)未见剂量限制性毒性,DL2(37.5 mg/天)出现1例4级血小板减少;DL2治疗19例患者6个月局部无进展率为73.3%(95%CI 44.9%-92.2%),中位无进展生存期6.5个月,中位总生存期未达到;作者认为该联合方案可行、有效,需进一步探索更新的多激酶抑制剂与放疗的联合。

要点

  • DL1(25 mg/天)未见剂量限制性毒性,DL2(37.5 mg/天)出现1例4级血小板减少。
  • DL2治疗19例患者6个月局部无进展率为73.3%(95%CI 44.9%-92.2%)。
  • DL2治疗患者中舒尼替尼相关≥3级不良事件发生率为58%。

核心结论

  • 这是首个评估舒尼替尼37.5 mg持续给药联合单纯放疗治疗非GIST肉瘤的试验,该联合方案被认为可行、有效,需进一步探索更新的多激酶抑制剂与放疗的联合。

研究设计与样本

  • 法国多中心3+3剂量递增Ⅰ期研究,纳入不可手术局部晚期或复发肉瘤、ECOG-PS<2、转移灶≤2个且无脑转移、器官功能充足且无未控制高血压、既往未接受舒尼替尼或放疗的患者。
  • 剂量递增阶段计划舒尼替尼剂量水平为DL1 25 mg/天、DL2 37.5 mg/天、DL3 50 mg/天,联合标准放疗60 Gy、30次、每周5次、共6周。
  • 主要终点为前14周剂量限制性毒性发生率和最大耐受剂量;2011年5月至2016年4月剂量递增阶段入组10例(DL1 4例,DL2 6例)。
  • DL2共治疗19例患者(包括扩展阶段13例),舒尼替尼中位给药时长42.7(2.8-79.1)天,放疗中位时长6.4(1-8)周。

主要发现

  • DL1未见剂量限制性毒性,DL2出现1例剂量限制性毒性(4级血小板减少)。
  • DL2治疗的19例患者中,除3例外均接受60 Gy(1例早期进展接受40 Gy,1例早期死亡接受8 Gy,1例处方剂量50 Gy)。
  • 中位随访19.5(14-36.5)个月,中位无进展生存期6.5(1.9-31.1)个月,中位总生存期未达到。
  • 6个月局部无进展率为73.3%(95%CI 44.9%-92.2%),1例患者在治疗后适合手术。
  • DL2治疗患者中舒尼替尼相关≥3级不良事件发生率为58%(递增阶段4例,扩展阶段7例),报告7例(36.8%)疾病进展相关死亡。

局限性

  • 原文结论指出需进一步探索更新的多激酶抑制剂与放疗的联合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Local control in sarcoma is rarely achieved with exclusive radiotherapy (RT). We aim to assess the feasibility and safety of sunitinib continuously administrated with concomitant RT in inoperable non-GIST sarcomas patients. METHODS: This multicentric French 3 + 3 dose escalation study included patients with inoperable locally advanced or recurrent sarcoma, ECOG-PS <2, ≤2 metastatic sites and no brain metastases, adequate organ functions and absence of uncontrolled hypertension, who had never received sunitinib or radiotherapy. The escalation phase planned to use sunitinib dose levels (DL1: 25; DL2: 37.5; DL3: 50 mg/day) with standard RT (60 Gy, 30 fractions, 5 fractions/week/6 weeks). The primary endpoint was to determine the incidence of dose-limiting toxicities (DLT) in the first 14 weeks and the maximal tolerated dose (MTD). Secondary endpoints included safety (acute and late toxicities), local control at 6 months including local progression free rate (L-PFR) progression free survival (PFS), overall survival (OS), proportion of patients eligible for surgery after treatment. RESULTS: From May 2011 to April 2016, the dose-escalation phase enrolled 10 patients (DL1 N = 4; DL2 N = 6). No DLT was observed in at DL1. One DLT (grade 4 thrombopenia) occurred at DL2. The 19 patients treated at DL2 (including the 13 patients from the expansion phase) received sunitinib for a median duration of 42.7 (2.8-79.1) days, and radiotherapy for 6.4 (1-8) weeks; all but 3 patients received 60 Gy (40 Gy, early progression (N = 1); 8 Gy, early death (N = 1), prescribed dose, 50 Gy (N = 1)). With a median follow-up of 19.5 (14-36.5) months, the median PFS was 6.5 (1.9-31.1) months. Median OS was not reached. At 6 months, L-PFR was 73.3% (95%CI 44.9%-92.2%). One patient was amendable to surgery after treatment. Sunitinib-related grade ≥ 3 adverse events occurred in 58% of the patients treated at DL2 (Escalation N = 4; Expansion N = 7). Seven (36.8%) deaths related to disease progression were reported. CONCLUSION: This is the first trial assessing the combination of continuous administration of sunitinib 37.5 mg with exclusive RT in non-GIST sarcoma. Whereas this combination was found feasible, efficient, further investigations of combinations of more recent multikinase inhibitors with RT need to be explored.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sunyach MP, Penel N, Montané L, et al. Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. Radiother Oncol. 2022. PMID: 35065999. doi:10.1016/j.radonc.2022.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。